Search

Hydroponics, a soil-less agriculture system, consumes less water and resources compared to traditional soil-based farming. However, it requires simultaneous monitoring of various parameters, making it challenging. This article explores a ground-breaking hydroponic system designed to revolutionize modern farming by creating a precision-controlled environment for plant growth. Our research developed a Smart Hydroponic farm using Internet of Things (IoT) technology to highlight its advantages over traditional humanintervened hydroponics. Given the high costs of organic farming, this paper offers a more feasible solution through automated hydroponics with remote monitoring and control. The system exemplifies smart agriculture by utilizing real-time sensors for light, pH, EC, temperature, water level, and a camera module, all managed by a Raspberry Pi processor. It aims to save labor and resources while providing precise control over watering and fertilization. The primary function of this hydroponic system is to automate parameter monitoring and control via actuators, facilitating faster production of green leafy vegetables and eliminating the labor-intensive tasks typically associated with farming. [ABSTRACT FROM AUTHOR]

Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15 and 40. Although most patients are cured, those with disease arising in the mediastinum have distinctly poor outcomes. One in every 17 patients with primary mediastinal nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly suggest a clonal relationship exists between hematologic malignancies and GCTs in these cases. To date, however, the precise clonal relationship between GCTs and the diverse additional somatic malignancies arising in such individuals have not been determined. Here, we traced the clonal evolution and characterized the genetic features of each neoplasm from a cohort of 15 patients with GCTs and associated hematologic malignancies. We discovered that GCTs and hematologic malignancies developing in such individuals evolved from a common shared precursor, nearly all of which harbored allelically imbalanced p53 and/or RAS pathway mutations. Hematologic malignancies arising in this setting genetically resembled mediastinal GCTs rather than de novo myeloid neoplasms. Our findings argue that this scenario represents a unique clinical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral precursor that gives rise to the parallel evolution of GCTs and blood cancers in these patients., Introduction Germ cell tumors (GCTs) are a model of curable cancer, as most patients with metastatic GCTs are successfully treated with cisplatin-based chemotherapy (1). However, up to 30% of patients [...]

The advent of Online Social Networks (OSNs) and the Internet-of-Things (IoT) has catalyzed an unprecedented surge in data generation at smart device endpoints. This phenomenon necessitates robust strategies for efficient data distribution and processing on data servers. Furthermore, the burgeoning volume of data intensifies challenges associated with data placement, replication, and migration in edge-cloud computing paradigms. Considerations such as access delay, cost implications, workload balance, and data security become critical parameters in the storage and processing of data from OSNs and IoT devices. Researchers have proposed various strategies to optimize data placement costs, access latency, migration costs, and load balancing constraints. This paper presents an extensive survey on the existing strategies for data placement, data replication, and data migration. The future research directions in edge-cloud computing informed by this survey are also delineated herein. [ABSTRACT FROM AUTHOR]

PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). We report on the primary outcome of objective response rate (ORR) and secondary endpoints of toxicity, clinical benefit, progression-free survival, overall survival, and durations of response/treatment. In 84 patients in 9 histotype cohorts, all patients experienced ≥1 adverse event and treatment-related adverse event; 1 death was possibly treatment-related. ORR was highest in angiosarcoma (3/8) and undifferentiated pleomorphic sarcoma (2/10), meeting predefined endpoints. Results of our exploratory investigation of predictive biomarkers show: CD8 + T cell infiltrates and PD-1 expression correlate with improved ORR; upregulation of immune-related pathways correlate with improved efficacy; Hedgehog pathway expression correlate with resistance. Exploration of this combination in selected sarcomas, and of Hedgehog signaling as a predictive biomarker, warrants further study in larger cohorts. The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma. [ABSTRACT FROM AUTHOR]